EA200700360A1 - Новые производные амида гетероциклической карбоновой кислоты - Google Patents

Новые производные амида гетероциклической карбоновой кислоты

Info

Publication number
EA200700360A1
EA200700360A1 EA200700360A EA200700360A EA200700360A1 EA 200700360 A1 EA200700360 A1 EA 200700360A1 EA 200700360 A EA200700360 A EA 200700360A EA 200700360 A EA200700360 A EA 200700360A EA 200700360 A1 EA200700360 A1 EA 200700360A1
Authority
EA
Eurasian Patent Office
Prior art keywords
new
hydrocyclic
amida
acid derivatives
carbonic acid
Prior art date
Application number
EA200700360A
Other languages
English (en)
Other versions
EA011635B1 (ru
Inventor
Иштван Борза
Чилла Хорват
Шандор Фаркаш
Иштван Дьертьян
Йожеф Надь
Шандор Колок
Корнел Галгоци
Каталин Саги
Original Assignee
Рихтер Гедеон Ведьесети Дьяр Рт.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Рихтер Гедеон Ведьесети Дьяр Рт. filed Critical Рихтер Гедеон Ведьесети Дьяр Рт.
Publication of EA200700360A1 publication Critical patent/EA200700360A1/ru
Publication of EA011635B1 publication Critical patent/EA011635B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)

Abstract

Настоящее изобретение касается новых производных амида гетероциклической карбоновой кислоты формулы (I), в которой значение Х соответствует водороду или атому галогена, гидрокси, циано, C
EA200700360A 2004-07-29 2005-07-21 Новые производные амида гетероциклической карбоновой кислоты EA011635B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0401527A HU227119B1 (en) 2004-07-29 2004-07-29 Indole and benzimidazole carboxylic acid amide derivatives and pharmaceutical compositions containing them
PCT/HU2005/000082 WO2006010969A1 (en) 2004-07-29 2005-07-21 New heterocyclic carboxylic acid amide derivatives

Publications (2)

Publication Number Publication Date
EA200700360A1 true EA200700360A1 (ru) 2007-06-29
EA011635B1 EA011635B1 (ru) 2009-04-28

Family

ID=89985412

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200700360A EA011635B1 (ru) 2004-07-29 2005-07-21 Новые производные амида гетероциклической карбоновой кислоты

Country Status (20)

Country Link
US (1) US20080300276A1 (ru)
EP (1) EP1771437A1 (ru)
JP (1) JP2008508251A (ru)
KR (1) KR20070038503A (ru)
CN (1) CN1989126A (ru)
AP (1) AP2076A (ru)
AU (1) AU2005266164A1 (ru)
BR (1) BRPI0513900A (ru)
CA (1) CA2574169A1 (ru)
EA (1) EA011635B1 (ru)
GE (1) GEP20084494B (ru)
HU (1) HU227119B1 (ru)
IL (1) IL179483A0 (ru)
MA (1) MA28818B1 (ru)
MX (1) MX2007001049A (ru)
NO (1) NO20071112L (ru)
TN (1) TNSN07014A1 (ru)
UA (1) UA88643C2 (ru)
WO (1) WO2006010969A1 (ru)
ZA (1) ZA200700329B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2520567A3 (en) 2006-02-23 2012-12-12 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
MX2012008721A (es) 2010-02-16 2012-08-17 Pfizer (r)-4-((4-((4-(tetrahidrofuran-3-iloxi)benzo[d]isoxazol-3-iloxi)m etil) tetrahidro-2h-piran-4-ol, un agonista pacial de receptores 5-ht4.
CA2958966C (en) 2014-08-28 2020-01-14 Asceneuron Sa Substituted cyclic amines as glucosidase inhibitors
WO2017106254A1 (en) * 2015-12-18 2017-06-22 Merck Sharp & Dohme Corp. Glycosidase inhibitors and uses thereof
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
JP6971999B2 (ja) 2016-02-25 2021-11-24 エースニューロン・ソシエテ・アノニム ピペラジン誘導体の酸付加塩
MA43680A (fr) 2016-02-25 2018-11-28 Asceneuron Sa Inhibiteurs de glycosidases
WO2017144633A1 (en) 2016-02-25 2017-08-31 Asceneuron S. A. Glycosidase inhibitors
US11213525B2 (en) 2017-08-24 2022-01-04 Asceneuron Sa Linear glycosidase inhibitors
WO2020039029A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Spiro compounds as glycosidase inhibitors
US12016852B2 (en) 2018-08-22 2024-06-25 Asceneuron Sa Pyrrolidine glycosidase inhibitors
WO2020039028A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Tetrahydro-benzoazepine glycosidase inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227197B1 (en) * 2000-10-24 2010-10-28 Richter Gedeon Nyrt Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
GEP20084494B (en) 2008-09-25
NO20071112L (no) 2007-02-27
WO2006010969A8 (en) 2006-08-31
AP2006003843A0 (en) 2006-12-31
IL179483A0 (en) 2007-05-15
UA88643C2 (ru) 2009-11-10
JP2008508251A (ja) 2008-03-21
EA011635B1 (ru) 2009-04-28
AU2005266164A1 (en) 2006-02-02
HU0401527D0 (en) 2004-09-28
WO2006010969A1 (en) 2006-02-02
HU227119B1 (en) 2010-07-28
AP2076A (en) 2009-12-17
EP1771437A1 (en) 2007-04-11
US20080300276A1 (en) 2008-12-04
KR20070038503A (ko) 2007-04-10
HUP0401527A2 (en) 2006-01-30
BRPI0513900A (pt) 2008-05-20
TNSN07014A1 (en) 2008-06-02
HUP0401527A3 (en) 2008-04-28
MA28818B1 (fr) 2007-08-01
MX2007001049A (es) 2007-04-16
ZA200700329B (en) 2008-05-28
CN1989126A (zh) 2007-06-27
CA2574169A1 (en) 2006-02-02

Similar Documents

Publication Publication Date Title
EA200700360A1 (ru) Новые производные амида гетероциклической карбоновой кислоты
SI2091948T1 (sl) Novi inhibitorji glutaminil ciklaze
EA200601391A1 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
HK1119699A1 (en) Pyridopyrimidinone inhibitors of pi3kalpha
MX2009003834A (es) Derivados de pirrolidina como inhibidores de iap.
EA200801608A1 (ru) Производные бензимидазолонкарбоновой кислоты
EA201000113A1 (ru) Пиразольные соединения
WO2007105058A8 (en) Pyrazole compounds
UA105185C2 (ru) Пирролы
ATE542813T1 (de) 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
TW200833675A (en) Nicotinamide derivatives
EA200970149A1 (ru) Производные n-(аминогетероарил)-1h-индол-2-карбоксамидов, их получение и их применение в терапии
UA105786C2 (ru) Аддитивные соли аминов, которые содержат гидроксильные и/или карбоксильные группы, с производными аминоникотиновой кислоты как ингибиторы dhodh
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
MX2010006063A (es) Derivados de 4-bencil-amino-pirrolidina 1,2-disustituida como inhibidores de la proteina de transferencia de colesteril-ester (cetp) utiles para el tratamiento de las enfermedades tales como hiperlipidemia o arterioesclerosis.
EA201170098A1 (ru) Замещенные производные алкилпиримидин-4-она
ATE517873T1 (de) 6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten
MX2010008360A (es) Derivados de oxazepinopirimidona heteroarilamida sustituidos.
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
MX2010008362A (es) Derivados de heteroarilamida diazepinopirimidona sustituidos.
MX2008016558A (es) Preparacion y aplicacion terapéutica de derivados de 2-benzoil-imidazopiridinas.
NO20085317L (no) Imidazoazepinonforbindelser
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU